Sign in

    Jackson Harvey

    Research Analyst at Nomura

    Jackson Harvey is an Analyst at Nomura specializing in biotechnology research, with specific coverage of companies such as Marker Therapeutics. Prior to Nomura, he served as a Biotech Equity Research Associate at Stifel Financial and as an Analyst at Deerfield Management, bringing a strong background in laboratory research and healthcare equity analysis. Harvey holds a Ph.D. from Weill Medical College of Cornell University and has conducted advanced biomedical research at institutions like Harvard Medical School. He is a Certified Pharmacy Technician and possesses extensive sector knowledge, though detailed investment performance metrics and professional securities licenses are not publicly listed.

    Jackson Harvey's questions to Marker Therapeutics (MRKR) leadership

    Jackson Harvey's questions to Marker Therapeutics (MRKR) leadership • Q1 2020

    Question

    Jackson Harvey, on behalf of Christopher Marai from Nomura, asked if the ongoing Baylor-sponsored trials, particularly the ADSPAM trial's new high-dose arm, have been impacted by the COVID-19 pandemic. He also questioned what specific data from the pancreatic cancer trial would be necessary for Marker to pursue it as a company-sponsored study.

    Answer

    Chief Medical Officer Dr. Mythili Koneru stated that while Baylor studies are generally proceeding, the treatment for one patient in the highest dose level of the Phase 1 AML study was delayed due to COVID-19. President and CEO Peter Hoang explained that for the pancreatic cancer program, the company is looking for further evidence of efficacy, including progression-free survival and overall survival data, to justify a company-sponsored trial.

    Ask Fintool Equity Research AI

    Jackson Harvey's questions to Marker Therapeutics (MRKR) leadership • Q3 2019

    Question

    Jackson Harvey from Nomura/Instinet inquired about the timeline for initiating patient dosing in the AML trial once the FDA clinical hold is resolved.

    Answer

    President and CEO Peter Hoang stated that trial preparations are ahead of schedule, with over 20 potential sites identified and awaiting an accepted IND number to begin contracting. He anticipates a prompt start to the trial immediately following the FDA's acceptance of their response and the lifting of the IND hold.

    Ask Fintool Equity Research AI